The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors
Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among others. Mutation R132H, which changes the functi...
Main Authors: | Katarzyna Malarz, Jacek Mularski, Marcin Pacholczyk, Robert Musiol |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/3/536 |
Similar Items
-
Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations
by: Katarzyna Malarz, et al.
Published: (2023-12-01) -
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01) -
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01) -
Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia
by: Ashkan Emadi, et al.
Published: (2016-03-01) -
Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
by: Gabriel Etienne, et al.
Published: (2019-09-01)